drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo and reinfused to mediate patient-specific, TCR-dependent antitumor cytotoxicity.
nci_thesaurus_concept_id
C200139
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs GT201 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes expanded ex vivo are reinfused to recognize patient-specific tumor antigens via their native T-cell receptors and kill tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine release, often supported by IL-2 to enhance expansion and persistence.
drug_name
GT201
nct_id_drug_ref
NCT06191900